| 1 | Impact of ethnicity on antiplatelet treatment regimens for bleeding reduction in acute coronary syndromes: a systematic review and pre-specified subgroup meta-analysis | 4.1 | 28 | Citations (PDF) |
| 2 | Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of Cardiology guidelines | 1.0 | 12 | Citations (PDF) |
| 3 | Aspirin-free antiplatelet strategies after percutaneous coronary interventions | 2.3 | 24 | Citations (PDF) |
| 4 | Pharmacological and clinical appraisal of factor XI inhibitor drugs | 4.1 | 23 | Citations (PDF) |
| 5 | Periprocedural myocardial infarction and injury | 1.0 | 14 | Citations (PDF) |
| 6 | Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis | 25.2 | 91 | Citations (PDF) |
| 7 | European Association of Cardio-Thoracic Surgery (EACTS) expert consensus statement on perioperative myocardial infarction after cardiac surgery | 1.4 | 27 | Citations (PDF) |
| 8 | Antithrombotic strategies for preventing graft failure in coronary artery bypass graft | 2.0 | 7 | Citations (PDF) |
| 9 | Risk Burden of Cancer in Patients Treated With Abbreviated Dual Antiplatelet Therapy After PCI: Analysis of Multicenter Controlled High-Bleeding Risk Trials | 5.7 | 17 | Citations (PDF) |
| 10 | Antiplatelet De-Escalation Strategies in Patients Undergoing Percutaneous Coronary Intervention | 5.7 | 7 | Citations (PDF) |
| 11 | Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome | 25.2 | 28 | Citations (PDF) |
| 12 | The pharmacology of antiplatelet agents for primary, secondary, and tertiary prevention of ischemic stroke | 2.2 | 1 | Citations (PDF) |
| 13 | P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis | 4.1 | 42 | Citations (PDF) |
| 14 | Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials | 4.1 | 19 | Citations (PDF) |
| 15 | Dual antiplatelet therapy in patients at high bleeding risk: less is more—more or less | 2.3 | 24 | Citations (PDF) |
| 16 | Pharmacology and Clinical Development of Factor XI Inhibitors | 25.2 | 123 | Citations (PDF) |
| 17 | Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation | 2.2 | 15 | Citations (PDF) |
| 18 | Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding | 2.3 | 26 | Citations (PDF) |
| 19 | Antithrombotic Management in AF Patients Following Percutaneous Coronary Intervention: A European Perspective | 1.4 | 14 | Citations (PDF) |
| 20 | Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis | 4.2 | 53 | Citations (PDF) |
| 21 | Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC) | 4.1 | 31 | Citations (PDF) |
| 22 | Overcoming professional barriers encountered by women in interventional cardiology: an EAPCI statement | 2.3 | 2 | Citations (PDF) |
| 23 | DOACs and rheumatic valvulopathy: always a red light? | 0.1 | 2 | Citations (PDF) |
| 24 | Low dose rivaroxaban for the management of atherosclerotic cardiovascular disease | 2.0 | 8 | Citations (PDF) |
| 25 | Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium | 25.2 | 139 | Citations (PDF) |
| 26 | Personalised antiplatelet therapies for coronary artery disease: what the future holds | 2.3 | 38 | Citations (PDF) |
| 27 | 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG | 2.3 | 47 | Citations (PDF) |
| 28 | Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial | 25.2 | 14 | Citations (PDF) |
| 29 | 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG | 1.4 | 39 | Citations (PDF) |
| 30 | Gender differences in efficacy and safety of antiplatelet strategies for acute coronary syndromes | 2.7 | 15 | Citations (PDF) |
| 31 | Bleeding in acute coronary syndrome: from definitions, incidence, and prognosis to prevention and management | 2.7 | 6 | Citations (PDF) |
| 32 | Navigating the Course of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Review of Guided Approaches | 5.7 | 5 | Citations (PDF) |
| 33 | Bleeding in acute coronary syndrome: from definitions, incidence, and prognosis to prevention and management | 2.7 | 7 | Citations (PDF) |
| 34 | Polymer-Free Biolimus-Eluting Stents or Polymer-Based Zotarolimus-Eluting Stents for Coronary Bifurcation Lesions | 0.7 | 3 | Citations (PDF) |
| 35 | Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials | 4.1 | 26 | Citations (PDF) |
| 36 | Oral antithrombotic therapy for the prevention of recurrent cerebrovascular events | 4.1 | 5 | Citations (PDF) |
| 37 | Ultrasound- Versus Fluoroscopy-Guided Femoral Access for Percutaneous Coronary Intervention of Chronic Total Occlusions: Insights From FOUND BLOOD CTO Registry | 0.7 | 8 | Citations (PDF) |
| 38 | Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials | 4.1 | 58 | Citations (PDF) |
| 39 | Efficacy and Safety of Aspirin for Primary Cardiovascular Risk Prevention in Younger and Older Age: An Updated Systematic Review and Meta-analysis of 173,810 Subjects from 21 Randomized Studies | 4.2 | 31 | Citations (PDF) |
| 40 | Anti-inflammatory strategies for atherosclerotic artery disease | 2.7 | 10 | Citations (PDF) |
| 41 | Current management and screening of peripheral and coronary artery disease in people with diabetes mellitus in Europe. The PADDIA/CADDIA survey | 6.2 | 5 | Citations (PDF) |
| 42 | ABCD‐GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR‐PCI Trial | 4.3 | 34 | Citations (PDF) |
| 43 | Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes | 3.2 | 101 | Citations (PDF) |
| 44 | European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis | 5.7 | 35 | Citations (PDF) |
| 45 | The Role of Antiplatelet Therapy in Patients With MINOCA | 2.6 | 16 | Citations (PDF) |
| 46 | Sex Differences in Outcomes After Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Left Main Disease: From the DELTA Registries | 4.3 | 13 | Citations (PDF) |
| 47 | P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention | 37.5 | 67 | Citations (PDF) |
| 48 | Antithrombotic therapy after transcatheter aortic valve implantation | 2.1 | 6 | Citations (PDF) |
| 49 | Antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack | 2.7 | 3 | Citations (PDF) |
| 50 | P2Y12 Inhibitor Monotherapy: Considerations for Acute and Long-Term Secondary Prevention Post-PCI | 1.2 | 16 | Citations (PDF) |
| 51 | Approaches to de-escalation of antiplatelet treatment in stabilized post-myocardial infarction patients with high ischemic risk | 1.9 | 6 | Citations (PDF) |
| 52 | Use of Intravascular Imaging in Patients With ST-Segment Elevation Acute Myocardial Infarction | 0.7 | 28 | Citations (PDF) |
| 53 | Effect of post‐procedural evidence‐based therapy on 2‐year prognosis after transcatheter mitral valve repair | 7.8 | 3 | Citations (PDF) |
| 54 | Unmasking psychological reasons of delay in acute coronary syndromes presentation during the COVID‐19 pandemic | 1.7 | 5 | Citations (PDF) |
| 55 | Choices in antithrombotic management for patients with atrial fibrillation undergoing percutaneous coronary intervention: questions (and answers) in chronological sequence | 4.1 | 9 | Citations (PDF) |
| 56 | Accuracy of the <scp>PARIS</scp> score and <scp>PCI</scp> complexity to predict ischemic events in patients treated with very thin stents in unprotected left main or coronary bifurcations | 1.7 | 7 | Citations (PDF) |
| 57 | Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI) | 4.1 | 57 | Citations (PDF) |
| 58 | Safety and efficacy of P2Y<sub>12</sub>inhibitor monotherapy in patients undergoing percutaneous coronary interventions | 2.7 | 26 | Citations (PDF) |
| 59 | Coronavirus Disease 2019–Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management | 4.3 | 136 | Citations (PDF) |
| 60 | Suitability for elderly with heart disease of a QR code-based feedback of drug intake: Overcoming limitations of current medication adherence telemonitoring systems. | 2.3 | 12 | Citations (PDF) |
| 61 | Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials | 2.3 | 143 | Citations (PDF) |
| 62 | Does the left circumflex coronary artery location impact on the success of chronic total occlusion recanalization? A single-center cohort study | 0.9 | 2 | Citations (PDF) |
| 63 | 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) | 2.3 | 8,378 | Citations (PDF) |
| 64 | Safe femoral access for STEMI patients and mortality in the new decade: Back to the future? | 1.7 | 0 | Citations (PDF) |
| 65 | Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients | 4.1 | 67 | Citations (PDF) |
| 66 | An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group | 4.1 | 180 | Citations (PDF) |
| 67 | At the peak of COVID-19 age and disease severity but not comorbidities are predictors of mortality: COVID-19 burden in Bergamo, Italy | 1.7 | 37 | Citations (PDF) |
| 68 | Differences in coronary artery disease and outcomes of percutaneous coronary intervention with drug-eluting stents in women and men | 1.9 | 23 | Citations (PDF) |
| 69 | #<scp>SoMe</scp> for #<scp>IC</scp>: Optimal use of social media in interventional cardiology | 1.7 | 9 | Citations (PDF) |
| 70 | Statistical methods for composite endpoints | 4.1 | 27 | Citations (PDF) |
| 71 | Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis | 52.8 | 208 | Citations (PDF) |
| 72 | Triple Therapy, Dual Therapy, and Modulation of Anticoagulation Intensity | 3.2 | 4 | Citations (PDF) |
| 73 | Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI) | 2.3 | 111 | Citations (PDF) |
| 74 | Canakinumab for Secondary Prevention of Coronary Artery Disease | 1.1 | 23 | Citations (PDF) |
| 75 | Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations | 2.7 | 44 | Citations (PDF) |
| 76 | Sex based analysis of the impact of red blood cell transfusion and vascular or bleeding complications related to TAVI – The TRITAVI-Women Study | 2.3 | 21 | Citations (PDF) |
| 77 | Diagnostic pathways in myocardial infarction with non-obstructive coronary artery disease (MINOCA) | 1.0 | 53 | Citations (PDF) |
| 78 | Sex‐Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria | 4.3 | 53 | Citations (PDF) |
| 79 | Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives | 4.3 | 75 | Citations (PDF) |
| 80 | Roadmap Consensus on Carotid Artery Plaque Imaging and Impact on Therapy Strategies and Guidelines: An International, Multispecialty, Expert Review and Position Statement | 2.6 | 48 | Citations (PDF) |
| 81 | 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice | 2.3 | 5,138 | Citations (PDF) |
| 82 | Bleeding avoidance strategies in percutaneous coronary intervention | 37.5 | 137 | Citations (PDF) |
| 83 | Antithrombotic Therapy After Transcatheter Aortic Valve Replacement | 3.2 | 61 | Citations (PDF) |
| 84 | Impact of Post-Procedural Change in Left Ventricle Systolic Function on Survival after Percutaneous Edge-to-Edge Mitral Valve Repair | 2.6 | 15 | Citations (PDF) |
| 85 | Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease | 25.2 | 63 | Citations (PDF) |
| 86 | Reflections after TWILIGHT study: a new era in secondary prevention without aspirin? | 0.1 | 0 | Citations (PDF) |
| 87 | Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials | 2.3 | 141 | Citations (PDF) |
| 88 | Appraising the contemporary role of aspirin for primary and secondary prevention of atherosclerotic cardiovascular events | 1.9 | 6 | Citations (PDF) |
| 89 | Safety and efficacy of polymer‐free biolimus‐eluting stents versus ultrathin stents in unprotected left main or coronary bifurcation: A propensity score analysis from the RAIN and CHANCE registries | 1.7 | 3 | Citations (PDF) |
| 90 | 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes | 2.3 | 5,948 | Citations (PDF) |
| 91 | Impact of structural features of very thin stents implanted in unprotected left main or coronary bifurcations on clinical outcomes | 1.7 | 16 | Citations (PDF) |
| 92 | Left Ventricular Size Predicts Clinical Benefit After Percutaneous Mitral Valve Repair for Secondary Mitral Regurgitation: A Systematic Review and Meta-Regression Analysis | 0.7 | 5 | Citations (PDF) |
| 93 | Comparison of Self-Expanding Bioprostheses for Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis | 25.2 | 152 | Citations (PDF) |
| 94 | Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk | 2.3 | 128 | Citations (PDF) |
| 95 | Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis | 2.3 | 21 | Citations (PDF) |
| 96 | Outcomes of renin–angiotensin–aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis | 4.1 | 21 | Citations (PDF) |
| 97 | An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus | 1.9 | 11 | Citations (PDF) |
| 98 | Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus | 25.2 | 43 | Citations (PDF) |
| 99 | Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis | 1.9 | 5 | Citations (PDF) |
| 100 | Safety and Efficacy of Double Antithrombotic Therapy With Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis | 4.3 | 69 | Citations (PDF) |
| 101 | Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI | 2.4 | 53 | Citations (PDF) |
| 102 | Early Adverse Impact of Transfusion After Transcatheter Aortic Valve Replacement | 5.7 | 36 | Citations (PDF) |
| 103 | Meta-analysis Comparing Outcomes of Self-Expanding Versus Balloon-Expandable Valves for Transcatheter Aortic Valve Implantation | 1.9 | 19 | Citations (PDF) |
| 104 | Selatogrel, a novel P2Y<sub>12</sub> inhibitor: a review of the pharmacology and clinical development | 4.0 | 32 | Citations (PDF) |
| 105 | Wearable cardioverter-defibrillator in patients at risk of sudden cardiac death: consensus document from Kalarus et al. contradicts current guideline recommendations—Authors’ reply | 2.1 | 0 | Citations (PDF) |
| 106 | Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel | 3.2 | 146 | Citations (PDF) |
| 107 | Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease | 37.5 | 115 | Citations (PDF) |
| 108 | How to Define Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves | 3.2 | 5 | Citations (PDF) |
| 109 | Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial | 2.9 | 21 | Citations (PDF) |
| 110 | Real‐world reasons and outcomes for 1‐month versus longer dual antiplatelet therapy strategies with a polymer‐free BIOLIMUS A9‐coated stent | 1.7 | 1 | Citations (PDF) |
| 111 | Wearable cardioverter-defibrillator to reduce the transient risk of sudden cardiac death in coronary artery disease: Authors’ reply | 2.1 | 0 | Citations (PDF) |
| 112 | Meta-Analysis Comparing P2Y12 Inhibitors in Acute Coronary Syndrome | 1.9 | 19 | Citations (PDF) |
| 113 | Defibrillators for prevention from sudden cardiac death: is it that easy?—Authors’ reply | 2.1 | 0 | Citations (PDF) |
| 114 | Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management | 37.5 | 84 | Citations (PDF) |
| 115 | Prevalence and morphological changes of carotid kinking and coiling in growth: an echo-color Doppler study of 2856 subjects between aged 0 to 96 years | 1.3 | 17 | Citations (PDF) |
| 116 | Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients | 2.4 | 195 | Citations (PDF) |
| 117 | Prevention of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention | 0.6 | 15 | Citations (PDF) |
| 118 | Defining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology | 4.1 | 23 | Citations (PDF) |
| 119 | Mechanisms of ST-segment elevation myocardial infarction in patients with atrial fibrillation, prior stenting and long-standing chronic coronary syndrome | 1.3 | 7 | Citations (PDF) |
| 120 | 2018 ESC/EACTS Guidelines on myocardial revascularization | 2.3 | 5,848 | Citations (PDF) |
| 121 | 2018 ESC/EACTS Guidelines on myocardial revascularization | 1.4 | 488 | Citations (PDF) |
| 122 | 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm So | 2.1 | 244 | Citations (PDF) |
| 123 | Aspirin for the primary prevention of cardiovascular disease: latest evidence | 1.9 | 22 | Citations (PDF) |
| 124 | Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA) | 2.1 | 84 | Citations (PDF) |
| 125 | Stroke After Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention: Incidence, Pathogenesis, and Outcomes | 4.3 | 70 | Citations (PDF) |
| 126 | Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI | 2.4 | 153 | Citations (PDF) |
| 127 | Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms | 2.7 | 34 | Citations (PDF) |
| 128 | Thrombotic Versus Bleeding Risk After Transcatheter Aortic Valve Replacement | 2.4 | 75 | Citations (PDF) |
| 129 | Five-year clinical outcomes after percutaneous edge-to-edge mitral valve repair: Insights from the multicenter GRASP-IT registry | 3.0 | 64 | Citations (PDF) |
| 130 | Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Lower Surgical Risk | 2.4 | 289 | Citations (PDF) |
| 131 | Antithrombotic pharmacotherapy after transcatheter aortic valve implantation: an update | 1.9 | 9 | Citations (PDF) |
| 132 | Optical coherence tomography evaluation of the absorb bioresorbable scaffold performance for overlap versus non-overlap segments in patients with coronary chronic total occlusion: insight from the GHOST-CTO registry | 1.3 | 6 | Citations (PDF) |
| 133 | Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions | 2.3 | 260 | Citations (PDF) |
| 134 | Defining high bleeding risk in patients undergoing percutaneous coronary
intervention: a consensus document from the Academic Research Consortium for High Bleeding
Risk | 2.3 | 491 | Citations (PDF) |
| 135 | Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention | 25.2 | 635 | Citations (PDF) |
| 136 | Switching between P2Y12 inhibitors: Rationale, methods, and expected consequences | 2.5 | 6 | Citations (PDF) |
| 137 | Daily risk of adverse outcomes in patients undergoing complex lesions revascularization: A subgroup analysis from the RAIN-CARDIOGROUP VII study (veRy thin stents for patients with left mAIn or bifurcatioN in real life) | 2.3 | 13 | Citations (PDF) |
| 138 | Impact of Final Kissing Balloon and of Imaging on Patients Treated on Unprotected Left Main Coronary Artery With Thin-Strut Stents (From the RAIN-CARDIOGROUP VII Study) | 1.9 | 22 | Citations (PDF) |
| 139 | Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting | 2.0 | 6 | Citations (PDF) |
| 140 | Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use | 2.0 | 64 | Citations (PDF) |
| 141 | Drug-eluting stents are not alike: does it matter? | 3.8 | 4 | Citations (PDF) |
| 142 | New-generation drug-eluting stents for left main coronary artery disease according to the EXCEL trial enrollment criteria: Insights from the all-comers, international, multicenter DELTA-2 registry | 2.3 | 5 | Citations (PDF) |
| 143 | European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism | 2.3 | 351 | Citations (PDF) |
| 144 | Management of left main disease: an update | 2.3 | 39 | Citations (PDF) |
| 145 | Progress with drug-eluting stents – are we done? | 4.1 | 1 | Citations (PDF) |
| 146 | Durability of transcatheter bioprosthetic aortic valves: the story so far | 4.1 | 8 | Citations (PDF) |
| 147 | Dual antiplatelet therapy after percutaneous coronary intervention: entering the final chapter? | 4.1 | 5 | Citations (PDF) |
| 148 | Statistical primer: methodology and reporting of meta-analyses† | 1.4 | 26 | Citations (PDF) |
| 149 | A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery | 3.2 | 102 | Citations (PDF) |
| 150 | Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry | 4.2 | 0 | Citations (PDF) |
| 151 | Incidence, Timing, Causes and Predictors of Early and Late Re-Hospitalization in Patients Who Underwent Percutaneous Mitral Valve Repair With the MitraClip System | 1.9 | 18 | Citations (PDF) |
| 152 | Early and Mid-Term Outcomes of Transcatheter Aortic Valve Replacement Using the New Generation Self-Expanding Corevalve Evolut R Device | 1.6 | 1 | Citations (PDF) |
| 153 | Canakinumab for secondary prevention of atherosclerotic disease | 3.1 | 19 | Citations (PDF) |
| 154 | Decision Analytic Markov Model Weighting Expected Benefits and Current Limitations of First-Generation Bioresorbable Vascular Scaffolds | 5.7 | 10 | Citations (PDF) |
| 155 | The year in cardiology 2017: coronary interventions | 2.3 | 1 | Citations (PDF) |
| 156 | Current Use of Intracoronary Imaging in Interventional Practice ― Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey ― | 1.4 | 42 | Citations (PDF) |
| 157 | Triple antithrombotic therapy after ACS and PCI in patients on chronic oral anticoagulation: updateHeart, 2018, 104, 1976-1983 | 4.3 | 9 | Citations (PDF) |
| 158 | High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome - Insight from the GEPRESS study | 2.3 | 21 | Citations (PDF) |
| 159 | Left main coronary artery disease: pathophysiology, diagnosis, and treatment | 37.5 | 99 | Citations (PDF) |
| 160 | Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary | 2.3 | 50 | Citations (PDF) |
| 161 | Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the <scp>E</scp>uropean <scp>M</scp>ulticentre <scp>GHOST</scp>‐<scp>EU</scp><scp>R</scp>egistry | 1.7 | 8 | Citations (PDF) |
| 162 | Vascular response and healing profile of everolimus-eluting bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: A one-year optical coherence tomography analysis from the GHOST-CTO registry | 2.3 | 8 | Citations (PDF) |
| 163 | Long‐term clinical and echocardiographic outcomes of Mitraclip therapy in patients nonresponders to cardiac resynchronization | 1.2 | 14 | Citations (PDF) |
| 164 | ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy | 2.4 | 339 | Citations (PDF) |
| 165 | Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease | 2.7 | 27 | Citations (PDF) |
| 166 | CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction | 4.0 | 19 | Citations (PDF) |
| 167 | Incidence of Long‐Term Structural Valve Dysfunction and Bioprosthetic Valve Failure After Transcatheter Aortic Valve Replacement | 4.3 | 99 | Citations (PDF) |
| 168 | Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions | 2.3 | 649 | Citations (PDF) |
| 169 | Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention | 37.5 | 201 | Citations (PDF) |
| 170 | Transcatheter or surgical treatment of severe aortic stenosis and coronary artery disease: A comparative analysis from the Italian OBSERVANT study | 2.3 | 44 | Citations (PDF) |
| 171 | Restenosis patterns after bioresorbable vascular scaffold implantation: Angiographic substudy of the <scp>GHOST</scp>‐<scp>EU</scp> registry | 1.7 | 4 | Citations (PDF) |
| 172 | Risk Stratification in Patients with Coronary Artery Disease: a Practical Walkthrough in the Landscape of Prognostic Risk Models | 1.4 | 24 | Citations (PDF) |
| 173 | Quo vadis, aspirin? | 4.1 | 2 | Citations (PDF) |
| 174 | Twitterature | 4.1 | 16 | Citations (PDF) |
| 175 | Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions | 4.1 | 132 | Citations (PDF) |
| 176 | Aspirin Desensitization in Patients With Coronary Artery Disease | 5.7 | 59 | Citations (PDF) |
| 177 | Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions | 3.2 | 16 | Citations (PDF) |
| 178 | Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds | 3.2 | 48 | Citations (PDF) |
| 179 | A Risk Model for Prediction of 1-Year Mortality in Patients Undergoing MitraClip Implantation | 1.9 | 40 | Citations (PDF) |
| 180 | Feasibility and predictors of early discharge after percutaneous edge-to-edge mitral valve repairHeart, 2017, 103, 931-936 | 4.3 | 8 | Citations (PDF) |
| 181 | Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures | 5.7 | 77 | Citations (PDF) |
| 182 | Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials | 2.3 | 48 | Citations (PDF) |
| 183 | Unusual interatrial membrane in the left atrium: A newer obstacle for transseptal‐based percutaneous mitral valve repair techniques? | 0.9 | 0 | Citations (PDF) |
| 184 | Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome | 2.0 | 9 | Citations (PDF) |
| 185 | Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) | 2.3 | 408 | Citations (PDF) |
| 186 | Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) | 1.4 | 193 | Citations (PDF) |
| 187 | Optimized Screening of Coronary Artery Disease With Invasive Coronary Angiography and Ad Hoc Percutaneous Coronary Intervention During Transcatheter Aortic Valve Replacement | 5.7 | 32 | Citations (PDF) |
| 188 | Clinical Outcomes Following Intravascular Imaging-Guided Versus Coronary Angiography–Guided Percutaneous Coronary Intervention With Stent Implantation | 3.2 | 253 | Citations (PDF) |
| 189 | Transcatheter Aortic Valve Implantation With or Without Percutaneous Coronary Artery Revascularization Strategy: A Systematic Review and Meta‐Analysis | 4.3 | 140 | Citations (PDF) |
| 190 | Impact of overlapping on 1‐year clinical outcomes in patients undergoing everolimus‐eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST‐EU registry | 1.7 | 15 | Citations (PDF) |
| 191 | Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry | 1.7 | 29 | Citations (PDF) |
| 192 | Antiplatelet therapy and outcome in patients undergoing surgery following coronary stenting: Results of the surgery after stenting registry | 1.7 | 27 | Citations (PDF) |
| 193 | Pretreatment with Antiplatelet Agents in the Setting of Percutaneous Coronary Intervention | 0.5 | 6 | Citations (PDF) |
| 194 | Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting | 0.5 | 4 | Citations (PDF) |
| 195 | Procedural Management of Patients With Advanced Heart Failure Undergoing MitraClip Implantation (From the GRASP Registry) | 1.4 | 11 | Citations (PDF) |
| 196 | Triaging patients with left main disease after the EXCEL and NOBLE trials: the everlasting saga of coronary artery bypass grafting and percutaneous coronary intervention | 1.3 | 0 | Citations (PDF) |
| 197 | Heparin versus bivalirudin for percutaneous coronary intervention: has the debate come to an end? | 1.3 | 3 | Citations (PDF) |
| 198 | Coronary revascularization strategies in patients with multivessel disease: is it all about diabetes? | 1.8 | 2 | Citations (PDF) |
| 199 | The DELTA 2 Registry | 3.2 | 46 | Citations (PDF) |
| 200 | Trancatheter aortic valve implantation and mitral valve repair: two trains, two speeds | 4.1 | 4 | Citations (PDF) |
| 201 | Late Self-Apposition With One-Year Persisting Uncoverage of Malapposed Bioresorbable Polymeric Struts | 2.6 | 0 | Citations (PDF) |
| 202 | Assessing Risk in Patients with Stable Coronary Disease: When Should We Intensify Care and Follow-Up? Results from a Meta-Analysis of Observational Studies of the COURAGE and FAME Era | 2.4 | 30 | Citations (PDF) |
| 203 | Overlapping meta-analyses of bioresorbable vascular scaffolds versus everolimus-eluting stents: bringing clarity or confusion? | 1.3 | 3 | Citations (PDF) |
| 204 | Early results of MitraClip system implantation by real-time three-dimensional speckle-tracking left ventricle analysis | 1.2 | 10 | Citations (PDF) |
| 205 | Everolimus‐eluting bioresorbable vascular scaffolds versus second generation drug‐eluting stents for percutaneous treatment of chronic total coronary occlusions: Technical and procedural outcomes from the G<scp>HOST‐CTO</scp> registry | 1.7 | 12 | Citations (PDF) |
| 206 | Impact of Culprit Plaque and Atherothrombotic Components on Incomplete Stent Apposition in Patients With ST-Elevation Myocardial Infarction Treated With Everolimus-Eluting Stents – An OCTAVIA Substudy – | 1.4 | 6 | Citations (PDF) |
| 207 | Revascularization of Unprotected Left Main Coronary Artery Disease | 5.7 | 4 | Citations (PDF) |
| 208 | Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement | 10.4 | 113 | Citations (PDF) |
| 209 | Real-world cost effectiveness of MitraClip combined with Medical Therapy Versus Medical therapy alone in patients with moderate or severe mitral regurgitation | 2.3 | 39 | Citations (PDF) |
| 210 | Radial Access Reduces Mortality in Patients With Acute Coronary Syndromes | 3.2 | 92 | Citations (PDF) |
| 211 | Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials | 1.0 | 77 | Citations (PDF) |
| 212 | Armazones bioabsorbibles y regresión de la placa: subir el listón en la tierra prometida del tratamiento de restauración vascular | 1.1 | 2 | Citations (PDF) |
| 213 | Bioresorbable Scaffolds and Plaque Regression: Raising the Bar in the Promised Land of Vascular Restoration Therapy | 0.5 | 2 | Citations (PDF) |
| 214 | Percutaneous mitral valve repair with the MitraClip system in the elderly: One-year outcomes from the GRASP registry | 2.3 | 22 | Citations (PDF) |
| 215 | Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus | 25.2 | 121 | Citations (PDF) |
| 216 | Joint EACVI HIT/EAPCI young survey/ESC CoT survey: training and education for ‘multimodality imaging in structural interventions’: the rise of a new sub-specialty? | 1.4 | 7 | Citations (PDF) |
| 217 | Bioresorbable Scaffolds | 0.5 | 6 | Citations (PDF) |
| 218 | Very late outcomes of drug-eluting stents: the ‘catch-down’ phenomenon | 2.3 | 8 | Citations (PDF) |
| 219 | Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease | 37.5 | 29 | Citations (PDF) |
| 220 | MitraClip Implantation for the Treatment of New-Onset Systolic Anterior Motion of the Mitral Valve After Transcatheter Aortic Valve Replacement | 2.3 | 7 | Citations (PDF) |
| 221 | Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization | 3.2 | 28 | Citations (PDF) |
| 222 | Risk stratification after ST-segment elevation myocardial infarction | 1.9 | 9 | Citations (PDF) |
| 223 | Update on clinical evidence (Part II): A summary of the main post market studies | 1.7 | 0 | Citations (PDF) |
| 224 | Risk prediction of contrast-induced nephropathy by ACEF score in patients undergoing coronary catheterization | 1.2 | 22 | Citations (PDF) |
| 225 | Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention | 1.0 | 16 | Citations (PDF) |
| 226 | Antithrombotic therapy following transcatheter aortic valve implantation: what challenge do we face? | 1.9 | 8 | Citations (PDF) |
| 227 | 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents | 3.2 | 24 | Citations (PDF) |
| 228 | Risk Stratification for Percutaneous Coronary Intervention | 0.5 | 7 | Citations (PDF) |
| 229 | Guía ESC 2015 sobre el tratamiento de pacientes con arritmiasventriculares y prevención de la muerte súbita cardiaca | 1.1 | 23 | Citations (PDF) |
| 230 | Reviewing the controversy surrounding pre-treatment with P2Y<sub>12</sub>inhibitors in acute coronary syndrome patients | 1.9 | 14 | Citations (PDF) |
| 231 | Bioresorbable scaffolds for calcified lesions: not a free lunch! | 4.1 | 1 | Citations (PDF) |
| 232 | Impact of chronic kidney disease on outcomes after percutaneous mitral valve repair with the MitraClip system: insights from the GRASP registry | 4.1 | 31 | Citations (PDF) |
| 233 | One-year outcomes after Absorb bioresorbable vascular scaffold implantation in routine clinical practice | 4.1 | 7 | Citations (PDF) |
| 234 | Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention | 4.1 | 31 | Citations (PDF) |
| 235 | Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment | 4.1 | 18 | Citations (PDF) |
| 236 | Transcatheter aortic valve durability and the dark side of Kaplan-Meier analysis | 4.1 | 5 | Citations (PDF) |
| 237 | Upcoming TAVI trials: rationale, design and impact on clinical practice | 4.1 | 13 | Citations (PDF) |
| 238 | Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry | 4.1 | 34 | Citations (PDF) |
| 239 | Will ABSORB III change my practice? Everolimus-eluting bioresorbable scaffolds for coronary artery disease | 4.1 | 0 | Citations (PDF) |
| 240 | Radial Versus Femoral Access in Invasively Managed Patients With Acute Coronary Syndrome | 10.4 | 91 | Citations (PDF) |
| 241 | Bivalirudin for acute coronary syndromes: premises, promises and doubts | 4.2 | 15 | Citations (PDF) |
| 242 | Anatomical features and management of bioresorbable vascular scaffolds failure: A case series from the <scp>GHOST</scp> registry | 1.7 | 32 | Citations (PDF) |
| 243 | Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery | 4.2 | 27 | Citations (PDF) |
| 244 | Antithrombotic treatment in patients undergoing transcatheter aortic valve implantation (TAVI) | 4.2 | 33 | Citations (PDF) |
| 245 | Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery | 4.2 | 54 | Citations (PDF) |
| 246 | New insights on acute expansion and longitudinal elongation of bioresorbable vascular scaffolds in vivo and at bench test: A note of caution on reliance to compliance charts and nominal length | 1.7 | 9 | Citations (PDF) |
| 247 | Management of adjunctive antithrombotic therapy in STEMI patients treated with fibrinolysis undergoing rescue or delayed PCI | 4.2 | 2 | Citations (PDF) |
| 248 | Eroded Versus Ruptured Plaques at the Culprit Site of STEMI | 7.0 | 94 | Citations (PDF) |
| 249 | Clinical, Angiographic, Functional, and Imaging Outcomes 12 Months After Implantation of Drug-Eluting Bioresorbable Vascular Scaffolds in Acute Coronary Syndromes | 3.2 | 38 | Citations (PDF) |
| 250 | Extended Use of Percutaneous Edge-to-Edge Mitral Valve Repair Beyond EVEREST (Endovascular Valve Edge-to-Edge Repair) Criteria | 3.2 | 113 | Citations (PDF) |
| 251 | Moderate and Severe Preoperative Chronic Kidney Disease Worsen Clinical Outcomes After Transcatheter Aortic Valve Implantation | 5.7 | 81 | Citations (PDF) |
| 252 | Impact of postoperative acute kidney injury on clinical outcomes after transcatheter aortic valve implantation: A meta‐analysis of 5,971 patients | 1.7 | 85 | Citations (PDF) |
| 253 | Morphine Is Associated With a Delayed Activity of Oral Antiplatelet Agents in Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention | 5.7 | 182 | Citations (PDF) |
| 254 | Meta-Analysis of Randomized Controlled Trials and Adjusted Observational Results of Use of Clopidogrel, Aspirin, and Oral Anticoagulants in Patients Undergoing Percutaneous Coronary Intervention | 1.9 | 65 | Citations (PDF) |
| 255 | Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era | 5.7 | 65 | Citations (PDF) |
| 256 | Five-year outcomes of percutaneous coronary intervention versus coronary artery bypass graft surgery in patients with left main coronary artery disease: An updated meta-analysis of randomized trials and adjusted observational studies | 2.3 | 22 | Citations (PDF) |
| 257 | Early discharge after transfemoral transcatheter aortic valve implantationHeart, 2015, 101, 1485-1490 | 4.3 | 90 | Citations (PDF) |
| 258 | Ventricular arrhythmias in aortic valve stenosis before and after transcatheter aortic valve implantation | 2.1 | 36 | Citations (PDF) |
| 259 | SYNTAX Score II predicts carotid disease in a multivessel coronary disease population | 2.3 | 5 | Citations (PDF) |
| 260 | One-Year Coverage by Optical Coherence Tomography of a Bioresorbable Scaffold Neocarina: Is It Safe to Discontinue Dual-Antiplatelet Therapy? | 2.6 | 0 | Citations (PDF) |
| 261 | Predictors of clinical outcomes after edge-to-edge percutaneous mitral valve repair | 3.0 | 100 | Citations (PDF) |
| 262 | Impact of moderate preoperative chronic kidney disease on mortality after transcatheter aortic valve implantation | 2.3 | 5 | Citations (PDF) |
| 263 | Effectiveness of MitraClip Therapy in Patients with Refractory Heart Failure | 1.4 | 22 | Citations (PDF) |
| 264 | A multidisciplinary consensus document on follow‐up strategies for patients treated with percutaneous coronary intervention | 1.7 | 8 | Citations (PDF) |
| 265 | Reply to the letter | 1.2 | 0 | Citations (PDF) |
| 266 | Managing Bioabsorbable Vascular Scaffold Failure: Combined Scaffold Restenosis and Late-Acquired Coronary Aneurysm Treated With Self-Expandable Stent | 2.6 | 11 | Citations (PDF) |
| 267 | Acute Kidney Injury With the RenalGuard System in Patients Undergoing Transcatheter Aortic Valve Replacement | 3.2 | 116 | Citations (PDF) |
| 268 | 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death | 2.1 | 659 | Citations (PDF) |
| 269 | Risk stratification for secondary prevention with ticagrelor and aspirin: A closer look to patient subsets from the PEGASUS-TIMI 54 trial | 2.3 | 3 | Citations (PDF) |
| 270 | Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy | 2.3 | 44 | Citations (PDF) |
| 271 | Revisiting Sex Equality With Transcatheter Aortic Valve Replacement Outcomes | 2.4 | 236 | Citations (PDF) |
| 272 | Comparison of Three Contemporary Surgical Scores for Predicting All-Cause Mortality of Patients Undergoing Percutaneous Mitral Valve Repair With the MitraClip System (from the Multicenter GRASP-IT Registry) | 1.9 | 49 | Citations (PDF) |
| 273 | Gender‐related clinical and echocardiographic outcomes at 30‐day and 12‐month follow up after <scp>M</scp>itra<scp>C</scp>lip implantation in the <scp>GRASP</scp> registry | 1.7 | 47 | Citations (PDF) |
| 274 | Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement | 4.1 | 22 | Citations (PDF) |
| 275 | Comparison of suture-based vascular closure devices in transfemoral transcatheter aortic valve implantation | 4.1 | 55 | Citations (PDF) |
| 276 | Lessons from the GHOST-EU registry | 4.1 | 17 | Citations (PDF) |
| 277 | What about the risk of thrombosis with bioresorbable scaffolds? | 4.1 | 25 | Citations (PDF) |
| 278 | Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry | 4.1 | 418 | Citations (PDF) |
| 279 | One-year outcomes in unselected patients treated with a thin-strut, platinum-chromium, paclitaxel-eluting stent: primary endpoint results from the TAXUS Element European post-approval surveillance study (TE-PROVE) | 4.1 | 5 | Citations (PDF) |
| 280 | Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective | 4.1 | 138 | Citations (PDF) |
| 281 | Incidence and potential mechanism of resolved, persistent and newly acquired malapposition three days after implantation of self-expanding or balloon-expandable stents in a STEMI population: insights from optical coherence tomography in the APPOSITION II study | 4.1 | 14 | Citations (PDF) |
| 282 | The EAPCI and continuing education for Fellows | 4.1 | 0 | Citations (PDF) |
| 283 | Three-Dimensional Angle Assessment and Plaque Distribution Classification in Left Main Disease: Impact of Geometry on Outcome | 1.2 | 1 | Citations (PDF) |
| 284 | Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System: 30-day and 12-month follow-up from the GRASP Registry | 1.4 | 139 | Citations (PDF) |
| 285 | Impact of Gene Polymorphisms, Platelet Reactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention | 3.2 | 42 | Citations (PDF) |
| 286 | Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes | 1.9 | 25 | Citations (PDF) |
| 287 | Usefulness and Validation of the Survival posT TAVI Score for Survival After Transcatheter Aortic Valve Implantation for Aortic Stenosis | 1.9 | 34 | Citations (PDF) |
| 288 | The SYNTAX score does not predict presence of carotid disease in a multivessel coronary disease population | 1.7 | 12 | Citations (PDF) |
| 289 | Positive airway pressure in patients with coronary artery disease and obstructive sleep apnea syndrome | 1.2 | 22 | Citations (PDF) |
| 290 | Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Ostial/Midshaft Lesions in Unprotected Left Main Coronary Artery From the DELTA Registry | 3.2 | 47 | Citations (PDF) |
| 291 | CABG versus PCI in diabetic patients with multivessel disease after risk stratification by the SYNTAX score: A pooled analysis of the SYNTAX and FREEDOM trials | 2.3 | 5 | Citations (PDF) |
| 292 | Comparison of Percutaneous Coronary Intervention (With Drug-Eluting Stents) Versus Coronary Artery Bypass Grafting in Women With Severe Narrowing of the Left Main Coronary Artery (from the Women–Drug-Eluting stent for LefT main coronary Artery disease Registry) | 1.9 | 14 | Citations (PDF) |
| 293 | Management of Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation in the Setting of Acute Coronary Syndromes or Percutaneous Coronary Interventions | 5.7 | 72 | Citations (PDF) |
| 294 | Volume‐to‐creatinine clearance ratio in patients undergoing coronary angiography with or without percutaneous coronary intervention: Implications of varying definitions of contrast‐induced nephropathy | 1.7 | 22 | Citations (PDF) |
| 295 | Spontaneous coronary artery dissection | 2.3 | 86 | Citations (PDF) |
| 296 | Mechanisms of Atherothrombosis and Vascular Response to Primary Percutaneous Coronary Intervention in Women Versus Men With Acute Myocardial Infarction | 3.2 | 93 | Citations (PDF) |
| 297 | Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So | 2.3 | 499 | Citations (PDF) |
| 298 | Mechanisms, Pathophysiology, and Clinical Aspects of Incomplete Stent Apposition | 2.4 | 125 | Citations (PDF) |
| 299 | Impact of Balloon Post-Dilation on Clinical Outcomes After Transcatheter Aortic Valve Replacement With the Self-Expanding CoreValve Prosthesis | 3.2 | 53 | Citations (PDF) |
| 300 | Residual platelet reactivity and outcomes with 5mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention | 2.3 | 9 | Citations (PDF) |
| 301 | A Simple Risk Tool (the OBSERVANT Score) for Prediction of 30-Day Mortality After Transcatheter Aortic Valve Replacement | 1.9 | 140 | Citations (PDF) |
| 302 | Prognostic Indicators for Recurrent Thrombotic Events in HIV-infected Patients with Acute Coronary Syndromes: Use of Registry Data From 12 sites in Europe, South Africa and the United States | 2.4 | 45 | Citations (PDF) |
| 303 | Meta-Analysis of Randomized Controlled Trials of Preprocedural Statin Administration for Reducing Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Catheterization | 1.9 | 48 | Citations (PDF) |
| 304 | Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study | 2.0 | 27 | Citations (PDF) |
| 305 | Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies | 4.1 | 133 | Citations (PDF) |
| 306 | Unmet needs of young interventional cardiologists: proceedings from the 2nd Summit of the European Association of Percutaneous Cardiovascular Interventions | 4.1 | 2 | Citations (PDF) |
| 307 | Usefulness of contrast injection during balloon aortic valvuloplasty before transcatheter aortic valve replacement: a pilot study | 4.1 | 14 | Citations (PDF) |
| 308 | Updating the evidence on patent foramen ovale closure versus medical therapy in patients with cryptogenic stroke: a systematic review and comprehensive meta-analysis of 2,303 patients from three randomised trials and 2,231 patients from 11 observational studies | 4.1 | 51 | Citations (PDF) |
| 309 | Emerging strategies for rapid reversal of anticoagulation in patients undergoing catheter-based interventions: aptamers enter the RADAR | 4.1 | 0 | Citations (PDF) |
| 310 | Tecnica di impianto dello scaffold coronarico riassorbibile Absorb(TM) nel registro IT-DISAPPEARS | 0.0 | 2 | Citations (PDF) |
| 311 | Lo studio PRAMI | 0.0 | 1 | Citations (PDF) |
| 312 | Impact of different stent alloys on human vascular response to everolimus‐eluting stent: An optical coherence tomography study: The OCTEVEREST | 1.7 | 28 | Citations (PDF) |
| 313 | Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: Impact of high on‐treatment platelet reactivity and diabetes mellitus status | 1.7 | 18 | Citations (PDF) |
| 314 | Optical coherence tomography guided in-stent thrombus removal in patients with acute coronary syndromes | 1.3 | 21 | Citations (PDF) |
| 315 | Incidence, Predictors, and Outcomes of Aortic Regurgitation After Transcatheter Aortic Valve Replacement | 2.4 | 756 | Citations (PDF) |
| 316 | Left ventricular reverse remodeling after transcatheter aortic valve implantation: a cardiovascular magnetic resonance study | 4.5 | 32 | Citations (PDF) |
| 317 | Long-Term Outcomes of Patients With Acute Coronary Syndrome and Nonobstructive Coronary Artery Disease | 1.9 | 70 | Citations (PDF) |
| 318 | Meta-analysis of everolimus-eluting stents versus first-generation drug-eluting stents in patients with left main coronary artery undergoing percutaneous coronary intervention | 2.3 | 6 | Citations (PDF) |
| 319 | Early and long-term outlook of percutaneous coronary intervention for bifurcation lesions in young patients | 2.3 | 4 | Citations (PDF) |
| 320 | Gender-related differences of diabetic patients undergoing percutaneous coronary intervention with drug-eluting stents: A real-life multicenter experience | 2.3 | 12 | Citations (PDF) |
| 321 | Management of Antiplatelet Therapy in Patients With Coronary Artery Disease Requiring Cardiac and Noncardiac Surgery | 25.2 | 101 | Citations (PDF) |
| 322 | Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for Ostial/Mid-Shaft Lesions Versus Distal Bifurcation Lesions in Unprotected Left Main Coronary Artery | 3.2 | 82 | Citations (PDF) |
| 323 | Paclitaxel versus sirolimus eluting stents in diabetic patients: Does stent type and/or stent diameter matter?: Long‐term clinical outcome of 2,429‐patient multicenter registry | 1.7 | 15 | Citations (PDF) |
| 324 | Initial experience of percutaneous coronary intervention in bifurcations with bioresorbable vascular scaffolds using different techniques — Insights from optical coherence tomography | 2.3 | 3 | Citations (PDF) |
| 325 | Antithrombotic Strategies in Valvular and Structural Heart Disease Interventions | 0.5 | 2 | Citations (PDF) |
| 326 | Incorporating Glomerular filtration rate or creatinine clearance by the modification of diet in renal disease equation or the Cockcroft–Gault equations to improve the Global Accuracy of the Age, Creatinine, Ejection Fraction [ACEF] score in patients undergoing percutaneous coronary intervention | 2.3 | 25 | Citations (PDF) |
| 327 | First-in-human description of everolimus-eluting bioabsorbable vascular scaffold implantation for the treatment of drug-eluting stent failure: Insights from optical coherence tomography | 2.3 | 14 | Citations (PDF) |
| 328 | One- and Twelve-Month Safety and Efficacy Outcomes of Patients Undergoing Edge-to-Edge Percutaneous Mitral Valve Repair (from the GRASP Registry) | 1.9 | 137 | Citations (PDF) |
| 329 | EuroSCORE II Versus Additive and Logistic EuroSCORE in Patients Undergoing Percutaneous Coronary Intervention | 1.9 | 17 | Citations (PDF) |
| 330 | Percutaneous recanalization of chronic total occlusions: Wherein lies the body of proof? | 3.0 | 31 | Citations (PDF) |
| 331 | Dual antiplatelet therapy in patients with diabetes mellitus: special considerations | 1.9 | 7 | Citations (PDF) |
| 332 | Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: A meta-analysis of 50,578 patients | 2.3 | 82 | Citations (PDF) |
| 333 | Usefulness of the logistic clinical SYNTAX score for predicting 1‐year mortality in patients undergoing percutaneous coronary intervention of the left main coronary artery | 1.7 | 6 | Citations (PDF) |
| 334 | Objectifying the impact of incomplete revascularization by repeat angiographic risk assessment with the residual SYNTAX score after left main coronary artery percutaneous coronary intervention | 1.7 | 32 | Citations (PDF) |
| 335 | Bridging antiplatelet therapy in patients requiring cardiac and non-cardiac surgery: from bench to bedside | 2.1 | 5 | Citations (PDF) |
| 336 | Current Status and Ongoing Development of Reversing Agents for Novel Oral Anticoagulants (NOACs) | 1.7 | 5 | Citations (PDF) |
| 337 | Pre-defining optimal C-arm position for TAVI with CT-scan using free software | 4.1 | 3 | Citations (PDF) |
| 338 | Unmet needs of young interventional cardiologists: the EAPCI Young survey | 4.1 | 7 | Citations (PDF) |
| 339 | Serial Assessment of Coronary Artery Response to Paclitaxel-Eluting Stents Using Optical Coherence Tomography | 5.7 | 26 | Citations (PDF) |
| 340 | Transcatheter aortic valve implantation: 3-year outcomes of self-expanding CoreValve prosthesis | 2.3 | 275 | Citations (PDF) |
| 341 | Lost in calculation: the Clinical SYNTAX score goes logistic | 2.3 | 7 | Citations (PDF) |
| 342 | Novel drugs for oral anticoagulation pharmacotherapy | 1.9 | 6 | Citations (PDF) |
| 343 | Facilitated/Pharmaco-invasive Approaches in STEMI | 2.0 | 11 | Citations (PDF) |
| 344 | Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial | 1.2 | 3 | Citations (PDF) |
| 345 | A focused update on emerging prognostic determinants in distal left main percutaneous coronary intervention | 2.3 | 5 | Citations (PDF) |
| 346 | Unraveling the EXCEL: Promises and challenges of the next trial of left main percutaneous coronary intervention | 2.3 | 24 | Citations (PDF) |
| 347 | Increasing CHADS2 scores may attenuate the benefit of novel oral anticoagulants versus warfarin in reducing intracranial bleeding | 2.3 | 5 | Citations (PDF) |
| 348 | Cigarette Smoking Is Associated With a Dose-Response Effect in Clopidogrel-Treated Patients With Diabetes Mellitus and Coronary Artery Disease | 3.2 | 49 | Citations (PDF) |
| 349 | Drug-Eluting Stent for Left Main Coronary Artery Disease | 3.2 | 127 | Citations (PDF) |
| 350 | Self-Expanding Versus Balloon-Expandable Stents in Acute Myocardial Infarction: Results From the APPOSITION II Study | 3.2 | 89 | Citations (PDF) |
| 351 | Comparative One-Year Effectiveness of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients <75 Versus ≥75 Years With Unprotected Left Main Disease (from the CUSTOMIZE Registry) | 1.9 | 16 | Citations (PDF) |
| 352 | Antithrombotic Therapy in Patients With Chronic Kidney Disease | 25.2 | 142 | Citations (PDF) |
| 353 | Prognostic implications of early and long‐term bleeding events in patients on one‐year dual antiplatelet therapy following drug‐eluting stent implantation | 1.7 | 11 | Citations (PDF) |
| 354 | Comparison of Complications and Outcomes to One Year of Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis | 1.9 | 62 | Citations (PDF) |
| 355 | Effect of Renal Artery Stenting on Left Ventricular Mass: A Randomized Clinical Trial | 1.4 | 50 | Citations (PDF) |
| 356 | Early‐ and mid‐term outcomes of transcatheter aortic valve implantation in patients with logistic EuroSCORE less than 20%: A comparative analysis between different risk strata | 1.7 | 33 | Citations (PDF) |
| 357 | Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus | 2.0 | 15 | Citations (PDF) |
| 358 | Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation | 2.0 | 24 | Citations (PDF) |
| 359 | Safety and effectiveness of the Catania Polyzene-F coated stent in real world clinical practice: 12-month results from the ATLANTA 2 registry | 4.1 | 9 | Citations (PDF) |
| 360 | Il processo decisionale clinico nella rivascolarizzazione del tronco comune della coronaria sinistra: passato, presente e futuro | 0.0 | 0 | Citations (PDF) |
| 361 | Impact of Insulin Receptor Substrate-1 Genotypes on Platelet Reactivity and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease | 2.4 | 59 | Citations (PDF) |
| 362 | Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft Surgery in Left Main Coronary Artery Disease | 2.4 | 189 | Citations (PDF) |
| 363 | Impact of Pentoxifylline on Platelet Function Profiles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel | 3.2 | 17 | Citations (PDF) |
| 364 | Incidence and Predictors of Early and Late Mortality After Transcatheter Aortic Valve Implantation in 663 Patients With Severe Aortic Stenosis | 25.2 | 1,076 | Citations (PDF) |
| 365 | Integrating the Synergy between percutaneous coronary intervention with Taxus and Cardiac Surgery (SYNTAX) score into practice: Use, pitfalls, and new directions | 3.0 | 34 | Citations (PDF) |
| 366 | Are propensity scores really superior to standard multivariable analysis? | 1.6 | 223 | Citations (PDF) |
| 367 | Routine versus selective coronary artery bypass for left main coronary artery revascularization: The appraise a customized strategy for left main revascularization (CUSTOMIZE) study | 2.3 | 1 | Citations (PDF) |
| 368 | Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial | 2.3 | 2 | Citations (PDF) |
| 369 | A post-hoc analysis of the CUSTOMIZE Registry on the differential impact of EuroSCORE and SYNTAX score in left main patients with intermediate Global Risk | 2.3 | 4 | Citations (PDF) |
| 370 | Daytime sleepiness does not predict sleep apnoea in patients with coronary artery disease | 2.3 | 10 | Citations (PDF) |
| 371 | Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease | 4.2 | 36 | Citations (PDF) |
| 372 | Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity | 4.2 | 29 | Citations (PDF) |
| 373 | Novel drug-eluting stents in the treatment of de novo coronary lesions | 2.7 | 18 | Citations (PDF) |
| 374 | Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease | 4.2 | 42 | Citations (PDF) |
| 375 | Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy | 4.2 | 37 | Citations (PDF) |
| 376 | Head-to-head comparison of early vessel healing by optical coherence tomography after implantation of different stents in the same patient | 1.2 | 10 | Citations (PDF) |
| 377 | Impact of diabetes mellitus on long-term follow-up of percutaneous coronary intervention based on clinical presentation of coronary artery disease | 1.2 | 8 | Citations (PDF) |
| 378 | Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation | 1.2 | 37 | Citations (PDF) |
| 379 | The Rapid Evaluation of Vessel Healing after Angioplasty (REVEAL) trial | 0.4 | 1 | Citations (PDF) |
| 380 | Does Occlusion Duration Influence Procedural and Clinical Outcome of Patients Who Underwent Percutaneous Coronary Intervention for Chronic Total Occlusion? | 1.4 | 13 | Citations (PDF) |
| 381 | Prevalence, Predictors, and Long-Term Prognosis of Premature Discontinuation of Oral Antiplatelet Therapy After Drug Eluting Stent Implantation | 1.9 | 116 | Citations (PDF) |
| 382 | Comparison of One-Year Outcomes of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Unprotected Left Main Coronary Artery Disease and Acute Coronary Syndromes (from the CUSTOMIZE Registry) | 1.9 | 39 | Citations (PDF) |
| 383 | Dual Antiplatelet Therapy Versus Aspirin Alone in Patients Undergoing Transcatheter Aortic Valve Implantation | 1.9 | 246 | Citations (PDF) |
| 384 | Is intravascular ultrasound beneficial for percutaneous coronary intervention of bifurcation lesions? Evidence from a 4,314-patient registry | 2.9 | 38 | Citations (PDF) |
| 385 | Global Risk Classification and Clinical SYNTAX (Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery) Score in Patients Undergoing Percutaneous or Surgical Left Main Revascularization | 3.2 | 126 | Citations (PDF) |
| 386 | Cardiovascular magnetic resonance for the assessment of patients undergoing transcatheter aortic valve implantation: a pilot study | 4.5 | 35 | Citations (PDF) |
| 387 | Validating the EXCEL hypothesis: A propensity score matched 3‐year comparison of percutaneous coronary intervention versus coronary artery bypass graft in left main patients with SYNTAX score ≤32 | 1.7 | 26 | Citations (PDF) |
| 388 | Pharmacodynamic Evaluation of Pantoprazole Therapy on Clopidogrel Effects | 5.7 | 39 | Citations (PDF) |
| 389 | Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease | 5.7 | 182 | Citations (PDF) |
| 390 | Impact of Drug-Eluting Stents and Diabetes Mellitus in Patients With Coronary Bifurcation Lesions: A Survey From the Italian Society of Invasive Cardiology | 5.7 | 9 | Citations (PDF) |
| 391 | Incidence rate and predictors of permanent pacemaker implantation after transcatheter aortic valve implantation with self-expanding CoreValve prosthesis | 2.1 | 59 | Citations (PDF) |
| 392 | Antithrombotic Pharmacotherapy in the Elderly: General Issues and Clinical Conundrums | 0.6 | 3 | Citations (PDF) |
| 393 | Prevalence of renal artery stenosis in patients undergoing cardiac catheterization | 3.2 | 13 | Citations (PDF) |
| 394 | Quality-of-life in elderly patients one year after transcatheter aortic valve implantation for severe aortic stenosis | 4.1 | 49 | Citations (PDF) |
| 395 | Trattamento della stenosi aortica grave. Problemi e aspettative | 0.0 | 0 | Citations (PDF) |
| 396 | Properties and Clinical Development of a Novel Coating Technology: The poly[bis(trifluoroethoxy)phosphazene] | 0.9 | 11 | Citations (PDF) |
| 397 | Sirolimus versus paclitaxel-eluting stents in small coronary vessels: long-term outcomes from a single-center registry | 1.2 | 7 | Citations (PDF) |
| 398 | Rapid Evaluation of Vessel HEaling After AngiopLasty (REVEAL) trial: rationale, objectives and design | 1.2 | 5 | Citations (PDF) |
| 399 | ClearWayRX System to reduce intracoronary thrombus in patients with acute coronary syndromes according to Optical Coherence Tomography after Abciximab Intracoronary Local infusion trial (COCTAIL): study rationale and design | 1.2 | 11 | Citations (PDF) |
| 400 | Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y<sub>12</sub>receptor antagonist | 1.9 | 83 | Citations (PDF) |
| 401 | Management of implant failure during transcatheter aortic valve implantation | 1.7 | 55 | Citations (PDF) |
| 402 | Plaque Distribution Patterns in Distal Left Main Coronary Artery to Predict Outcomes After Stent Implantation | 3.2 | 33 | Citations (PDF) |
| 403 | Local Delivery Versus Intracoronary Infusion of Abciximab in Patients With Acute Coronary Syndromes | 3.2 | 77 | Citations (PDF) |
| 404 | A Novel 3‐D Reconstruction System for the Assessment of Bifurcation Lesions Treated by the Mini‐Crush Technique | 1.4 | 15 | Citations (PDF) |
| 405 | Prognostic Value of Exercise Myocardial Scintigraphy in Patients with Coronary Chronic Total Occlusions | 1.4 | 32 | Citations (PDF) |
| 406 | Impact of race and gender on antithrombotic therapy | 4.2 | 74 | Citations (PDF) |
| 407 | Pharmacodynamic Effects of Concomitant Versus Staggered Clopidogrel and Omeprazole Intake | 5.7 | 62 | Citations (PDF) |
| 408 | Platelet thrombin receptor antagonism and atherothrombosis | 2.3 | 227 | Citations (PDF) |
| 409 | Transcatheter aortic valve implantation: what has been done and what is going to be done | 1.1 | 9 | Citations (PDF) |
| 410 | Percutaneous mitral valve repair with the MitraClip system: acute results from a real world setting | 2.3 | 236 | Citations (PDF) |
| 411 | Impact of Chronic Kidney Disease on Platelet Function Profiles in Diabetes Mellitus Patients With Coronary Artery Disease Taking Dual Antiplatelet Therapy | 2.4 | 199 | Citations (PDF) |
| 412 | Antithrombotic Therapy in the Elderly | 2.4 | 134 | Citations (PDF) |
| 413 | Sirolimus- vs. paclitaxel-eluting stents in patients undergoing off-label percutaneous coronary intervention | 2.3 | 0 | Citations (PDF) |
| 414 | EuroSCORE refines the predictive ability of SYNTAX score in patients undergoing left main percutaneous coronary intervention | 3.0 | 112 | Citations (PDF) |
| 415 | Intraoperative defibrillation threshold testing during implantable cardioverter-defibrillator insertion: Do we really need it? | 3.0 | 21 | Citations (PDF) |
| 416 | Real-world outcome of coronary bifurcation lesions in the drug-eluting stent era: Results from the 4,314-patient Italian Society of Invasive Cardiology (SICI-GISE) Italian Multicenter Registry on Bifurcations (I-BIGIS) | 3.0 | 41 | Citations (PDF) |
| 417 | Long-term outcomes after drug-eluting stent for the treatment of ostial left anterior descending coronary artery lesions | 3.0 | 23 | Citations (PDF) |
| 418 | Appraising the impact of left ventricular ejection fraction on outcomes of percutaneous drug-eluting stenting for unprotected left main disease: insights from a multicenter registry of 975 patients | 2.9 | 23 | Citations (PDF) |
| 419 | Epidemiology and clinical impact of different anatomical phenotypes of the left main coronary artery | 1.3 | 11 | Citations (PDF) |
| 420 | Clinical Development of Selective Anticoagulants: A State of the Art | 1.1 | 3 | Citations (PDF) |
| 421 | Impact of right coronary artery disease on mortality in patients undergoing percutaneous coronary intervention of unprotected left main coronary artery disease | 4.1 | 10 | Citations (PDF) |
| 422 | Diabetes mellitus: the scary killer haunting silently | 4.1 | 6 | Citations (PDF) |
| 423 | Are drug-eluting stents superior to bare-metal stents in patients with unprotected non-bifurcational left main disease? Insights from a multicentre registry | 2.3 | 51 | Citations (PDF) |
| 424 | Quality of life assessment after percutaneous aortic valve implantation | 2.3 | 86 | Citations (PDF) |
| 425 | Usefulness of the SYNTAX Score for Predicting Clinical Outcome After Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery Disease | 5.7 | 199 | Citations (PDF) |
| 426 | Comparison of Drug-Eluting Stents and Bare-Metal Stents for the Treatment of Unprotected Left Main Coronary Artery Disease in Acute Coronary Syndromes | 1.9 | 37 | Citations (PDF) |
| 427 | Optical Coherence Tomographic Results at Six-Month Follow-Up Evaluation of the CATANIA Coronary Stent System With NanoThin Polyzene-F Surface Modification (from the Assessment of The LAtest Non-Thrombogenic Angioplasty Stent [ATLANTA] Trial) | 1.9 | 20 | Citations (PDF) |
| 428 | Early and mid-term clinical outcomes with the CATANIA coronary stent system vs. bare metal stents in patients with coronary artery disease | 0.7 | 4 | Citations (PDF) |
| 429 | Real world safety and efficacy of the Janus tacrolimus‐eluting stent: Long‐term clinical outcome and angiographic findings from the tacrolimus‐eluting stent (TEST) registry | 1.7 | 25 | Citations (PDF) |
| 430 | Long‐term clinical benefit of drug‐eluting stents over bare‐metal stents in diabetic patients with <i>de novo</i> left main coronary artery disease: Results from a real‐world multicenter registry | 1.7 | 5 | Citations (PDF) |
| 431 | Percutaneous closure of patent foramen ovale with a bioabsorbable occluder device | 1.7 | 27 | Citations (PDF) |
| 432 | A novel approach to define risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents: the DERIVATION score | 2.9 | 12 | Citations (PDF) |
| 433 | Early Conduction Disorders Following Percutaneous Aortic Valve Replacement | 1.2 | 71 | Citations (PDF) |
| 434 | Mini-Crush Versus T-Provisional Techniques in Bifurcation Lesions | 3.2 | 36 | Citations (PDF) |
| 435 | First-in-Man 1-Year Clinical Outcomes of the Catania Coronary Stent System With Nanothin Polyzene-F in De Novo Native Coronary Artery Lesions | 3.2 | 30 | Citations (PDF) |
| 436 | Usefulness of SYNTAX Score to Select Patients With Left Main Coronary Artery Disease to Be Treated With Coronary Artery Bypass Graft | 3.2 | 154 | Citations (PDF) |
| 437 | Transesophageal echocardiography and transcranial color Doppler: independent or complementary diagnostic tests for cardiologists in the detection of patent foramen ovale? | 1.2 | 15 | Citations (PDF) |
| 438 | Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry | 1.2 | 3 | Citations (PDF) |
| 439 | Long-term follow-up after drug eluting stent implantation in left main trifurcations | 4.1 | 13 | Citations (PDF) |
| 440 | Comparison of optical coherence tomography and intravascular ultrasound for the assessment of in-stent tissue coverage after stent implantation | 4.1 | 55 | Citations (PDF) |
| 441 | Pursuing the goal to improve downstream myocardial tissue perfusion | 2.3 | 1 | Citations (PDF) |
| 442 | Early discharge in acute myocardial infarction after clinical and angiographic risk assessment | 1.2 | 5 | Citations (PDF) |
| 443 | Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients | 0.2 | 120 | Citations (PDF) |
| 444 | Anticoagulation after Transcatheter Aortic Valve Implantation: Current Status | 1.4 | 30 | Citations (PDF) |
